Table 3.

Phase II Survey B Results with Proposed Domains and Items During New Antiphospholipid Syndrome Classification Criteria Development

Proposed Domains (n:6)	Proposed Items (n:27)
Candidate Laboratory Criteria
1A: Antiphospholipid Antibody Testing-Coagulation-based Functional Assays	• Lupus Anticoagulant Test
1B:Antiphospholipid Antibody Testing-Solid Phase Assays	• Anticardiolipin Antibody IgG, Anticardiolipin Antibody IgM • Anti-β2-glycoprotein-I IgG, Anti-β2-glycoprotein-I IgM
Candidate Clinical Criteria
2: Macrovascular	• Superficial Vein Thrombosis, Venous Thromboembolism, Arterial Thrombosis, Transient Ischemic Attack
3: Microvascular	• Livedo Racemosa, Livedoid Vasculopathy, Adrenal Hemorrhage or Plexus Thrombosis, Acute Ischemic Encephalopathy, Cardiac Microvascular Disease, Pulmonary Hemorrhage, Acute aPL Nephropathy, Chronic aPL Nephropathy
4: Obstetric	• Pregnancy Loss <10 weeks (w) of Gestation, Fetal Death Between 10w to <16w of Gestation, Fetal Death Between 16w to 34w of Gestation, Pre-eclampsia with Severe Features <34w of Gestation, Placental Insufficiency with Severe Features <34w of Gestation
5: Cardiac Valve Disease	• Non-infectious Valve Vegetation, Thickening
6: Hematologic	• Platelet count <20 × 109 per liter, Platelet count 20 – 130 × 109 per liter, Platelet count 131–150 × 109 per liter